Johnson & Johnson (JNJ) Interest & Investment Income (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Interest & Investment Income came in at $219.0 million in Q2 2026, down 15.77% year-over-year from $260.0 million in Q2 2025, and down 4.37% quarter-over-quarter from $229.0 million in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Interest & Investment Income (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Interest & Investment Income across 18 years of filings, most recently posting $219.0 million for Q2 2026.
- In Q2 2026, Interest & Investment Income fell 15.77% year-over-year to $219.0 million; the TTM figure through Jun 2026 stood at $912.0 million (down 21.72% YoY), while the FY2025 annual figure was $1.1 billion, down 20.72% from the prior year.
- Interest & Investment Income came in at $219.0 million for Q2 2026 at Johnson & Johnson, down from $229.0 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $450.0 million in Q1 2023 to a low of $22.0 million in Q2 2022.
- Average Interest & Investment Income over 5 years is $265.7 million, with a median of $270.5 million recorded in 2024.
- Year-over-year, Interest & Investment Income soared 1053.85% in 2022 and slumped 34.18% in 2025.
- Over 5 years, Interest & Investment Income stood at $150.0 million in 2022, then soared by 142.0% to $363.0 million in 2023, then dropped by 22.59% to $281.0 million in 2024, then slipped by 15.66% to $237.0 million in 2025, then slipped by 7.59% to $219.0 million in 2026.
- Per Business Quant data, the three most recent Interest & Investment Income figures were $219.0 million in Q2 2026, $229.0 million in Q1 2026, and $237.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 219.00 Mn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | -679.00 Mn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | - |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 89.50 Mn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 35.58 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 38.12 Mn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 31.50 Mn |
| 10 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 12.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 219.00 Mn |
| Mar 29, 2026 | 229.00 Mn |
| Dec 28, 2025 | 237.00 Mn |
| Sep 28, 2025 | 227.00 Mn |
| Jun 29, 2025 | 260.00 Mn |
| Mar 30, 2025 | 332.00 Mn |
| Dec 29, 2024 | 281.00 Mn |
| Sep 29, 2024 | 292.00 Mn |
| Jun 30, 2024 | 395.00 Mn |
| Mar 31, 2024 | 364.00 Mn |
| Dec 31, 2023 | 363.00 Mn |
| Oct 1, 2023 | 374.00 Mn |
| Jul 2, 2023 | 326.00 Mn |
| Apr 2, 2023 | 198.00 Mn |
| Jan 1, 2023 | 450.00 Mn |
| Oct 2, 2022 | 150.00 Mn |
| Jul 3, 2022 | 64.00 Mn |
| Apr 3, 2022 | 22.00 Mn |
| Oct 3, 2021 | 13.00 Mn |
| Jul 4, 2021 | 12.00 Mn |